Anika Therapeutics (ANIK) Misses Q1 EPS by 62c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.11 +1.15%
Revenue Growth %: +5.5%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +5.5%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.46), $0.62 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $21.26 million versus the consensus estimate of $24.34 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Morgan Stanley Starts ARCHION Corp (543A:JP) at Equalweight
- UBS Upgrades Zhejiang Leapmotor Technology (9863:HK) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
